Measuring of inflammatory markers in serum (CRP, IL-6, IL-8) before induction of anesthesia, then 12 hours and 36 hours following the completion of surgery
The Anti-inflammatory Effect of Anesthetics in Abdominal Surgery
Brief Summary
Clinical studies have shown that IV administration of anesthetics, lidocaine and ketamine with their anti-inflammatory properties, modulates the acute immune response associated with surgical tissue injury, and in this manner they are able to reduce postoperative pain. Lidocaine has anti-inflammatory effects on polymorphonuclear granulocytes, IL-6 and IL-8 cytokines, complement component C3a and IL-1ra in serum. Ketamine produces its anti-inflammatory effects by reducing CRP and IL-6 in serum and by inhibiting NF-kB, which regulates gene transcription responsible for the production of proinflammatory factors.
Perioperative combinend IV administration of lidocaine and ketamine could have a more favorable anti-inflammatory effect compared to anesthetic given alone or with placebo.
To investigate the effects of lidocaine and ketamine in patients undergoing abdominal surgery on: acute immune response following the level of proinflammatory factors in serum (CRP, IL-6, IL-8); postoperative pain management; recovery of bowel function; administration of opioids; reduction of total treatment costs; length of hospital stay (LOHS)
A double-blind, placebo-controlled study will include 100 patients undergoing open colorectal surgery. Patients will be randomly assigned to one of four groups: lidocaine, ketamine, lidocaine-ketamine, and placebo. Lidocaine will be administered at a dose of 1.5 mg/kg prior to surgical incision followed by an infusion at a rate of 1.5-2 mg/kg/hr until the end of surgery. Ketamine will be administered at a dose of 0.5 mg/kg in a bolus prior to surgical incision followed by an infusion at a rate of 0.1-0.2 mg/kg/hr until the end of surgery. Bolus and continuous placebo infusion (0.9% NaCl) will be equally administered at the same dose as the aforementioned anesthetics until the end of the surgery.
Proinflammatory markers in serum (CRP, IL-6, IL-8) will be measured before induction of anesthesia, then 12 hours and 36 hours following the completion of surgery. The intensity of pain will be measured using the VAS score 2 hours and 4 hours following surgery and every 12 hours the following days. The investigators will measure also the consumption of opioids during and after surgery, the length of stay in the ICU, where pain control and analgesics use will be measured, as well as recovery of bowel function.
Intervention / Treatment
-
Lidocaine (OTHER)Lidocaine will be administered at a dose of 1.5 mg/kg prior to surgical incision followed by an infusion at a rate of 1.5-2 mg/kg/hr until the end of surgery.
-
Ketamine (OTHER)Ketamine will be administered at a dose of 0.5 mg/kg in a bolus prior to surgical incision followed by an infusion at a rate of 0.1-0.2 mg/kg/hr until the end of surgery.
-
Lidocaine and Ketamine (OTHER)Lidocaine will be administered at a dose of 1.5 mg/kg prior to surgical incision followed by an infusion at a rate of 1.5-2 mg/kg/hr until the end of surgery. Ketamine will be administered at a dose of 0.5 mg/kg in a bolus prior to surgical incision followed by an infusion at a rate of 0.1-0.2 mg/kg/hr until the end of surgery.
-
Placebo (0.9% NaCl) (OTHER)Bolus and continuous placebo infusion (0.9% NaCl) will be equally administered at the same dose as the aforementioned anesthetics until the end of the surgery.
Condition or Disease
- Colorectal Cancer
Phase
Study Design
Study type: | INTERVENTIONAL |
---|---|
Status: | Completed |
Study results: | No Results Available |
Age: | 18 Years to 75 Years |
Enrollment: | 82 (ACTUAL) |
Funded by: | Other |
Allocation: | Randomized |
Primary Purpose: | Other |
MaskingDOUBLE:
|
Clinical Trial Dates
Start date: | Jan 28, 2019 | ACTUAL |
---|---|---|
Primary Completion: | Jun 12, 2021 | ACTUAL |
Completion Date: | Jun 18, 2021 | ACTUAL |
Study First Posted: | Jan 30, 2019 | ACTUAL |
Results First Posted: | Aug 31, 2020 | |
Last Updated: | May 14, 2022 |
Sponsors / Collaborators
Lead Sponsor:
University Hospital Dubrava
Responsible Party:
N/A
Location
Participant Groups
-
No description provided
-
No description provided
-
No description provided
-
No description provided
Eligibility Criteria
Sex: | All |
---|---|
Minimum Age: | 18 |
Maximum Age: | 75 |
Age Groups: | Adult / Older Adult |
Healthy Volunteers: | Yes |
Inclusion Criteria:
* Elective Surgery
* Expected duration of the operation \> 2 hours
Exclusion Criteria:
* Patients ≤ 18 years of age
* Patients with history of allergy to local anesthetics
* Chronic opioid analgesic
* Patients who are unwilling or unable to participate
* Elective Surgery
* Expected duration of the operation \> 2 hours
Exclusion Criteria:
* Patients ≤ 18 years of age
* Patients with history of allergy to local anesthetics
* Chronic opioid analgesic
* Patients who are unwilling or unable to participate
Primary Outcomes
Secondary Outcomes
-
Measuring of total opioid consumption during intraoperative period
-
Measuring pain scores VAS scores 2 hours and 4 hours following surgery and every 12 hours the following 2 days.
-
Measuring total analgesic consumption for 48 hours following the completion of surgery
-
Measuring time to firs bowel movement
-
Follow-up patients until hospital discharge
More Details
NCT Number: | NCT03821545 |
---|---|
Other IDs: | Ostovic |
Study URL: | https://clinicaltrials.gov/study/NCT03821545 |
Last updated: Sep 29, 2023